|By PR Newswire||
|April 7, 2014 05:16 PM EDT||
DALLAS, April 7, 2014 /PRNewswire-iReach/ -- Alzheimer's disease drug market is on the curvature stage. Since 2003, there is not any single "magic bullet" launched in the market to prevent or cure it. However, all current marketed products are going to be generic in the next 3-4 years. There are high unmet medical needs. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies. If successful, they will be in a position to command premium prices and tap the existing opportunity. Lot of drugs has failed in Phase III stage thus putting a greater impact on Alzheimer's disease drug market.
From the year 2009 Alzheimer's disease drug market is declining and it is expected to fall till 2016. But with the expected launch of some Alzheimer's drugs from the year 2017 onwards, Alzheimer's disease drug market is expected to revive in the coming years. However due to absence of exact potential drugs there will always remain a huge Unmet Alzheimer's Drug Market. For the year 2018 Alzheimer 's disease Drug Market will be just 10% of Unmet Alzheimer's Disease Drug Market.
This report provides a comprehensive assessment of the fast-evolving, high-growth Global Alzheimer's Disease Market. This 110 page report with 29 Figures and 11 Tables studies the Global Alzheimer's Disease Drug Market.
Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=157418 .
Present & Pipeline Drugs Studied in this Report
This report contains 10 chapters.
(Chapter 1): Executive Summary
(Chapter 2): This Chapter is divided into 2 parts
A. Alzheimer's Disease Drug Market & Forecast data available from 2003 to 2018
B. Unmet Alzheimer's Disease Drug Market & Forecast (Market Potential) data available from 2010 to 2018. (Unmet market is the potential market which could have been achieved if right drug have been introduced in the market)
(Chapter 3): This chapter talks about drugs which has failed while in Clinical trials
(Chapter 4): This chapter provides Market Share of Alzheimer's Disease Drug from 2003 to 2018. All the 9 Alzheimer's drug mentioned above have been covered in this chapter.
(Chapter 5): This chapter talks about Alzheimer's Drugs performance. All important drugs mentioned above past, present & future market data available from 2003 to 2018.
(Chapter 6): Pipeline drugs (Solanezumab, LuAE58054, Gantenerumab, Crenezumab, TRx0237 (LMTX), MK-8931, ABT-126, AZD-1446) have been analyzed in this chapter. All drugs have been analyzed from 5 view points:
A. Clinical Development Stage
B. Pipeline Drug Sales Performance
C. Recent Clinical Development
D. Different Companies Deal
(Chapter 7): This chapter speaks of Alzheimer's Drugs Company deals in four areas
A. Strategic Alliances in Alzheimer's Disease Drug Market
B. Licensing Agreement in Alzheimer's Disease Drug Market
C. Collaboration Deal in Alzheimer's Disease Drug Market
D. Merger & Acquisition in Alzheimer's Disease Drug Market
(Chapter 8): This chapter studies Funding in Alzheimer's Disease Drugs Research. We have covered 5 institutes which provides fund for the research.
A. National Institute of Health
B. Alzheimer's Association
C. Cure Alzheimer's Fund
D. Alzheimer's Drug Discovery Foundation
E. Bright Focus Foundation [formerly American Health Assistance Foundation (AHAF)]
(Chapter 9): This chapter studies Growth Factors Driving the Alzheimer's Disease Drug Market.
(Chapter 10): This chapter studies Challenges/Hindrances faced by Alzheimer's Disease Drug Market.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
Comprehensive Table of Contents and more for the report "Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast – Global Analysis" is available at http://www.rnrmarketresearch.com/alzheimers-pipeline-drugs-review-alzheimers-disease-drug-market-forecast-global-analysis-market-report.html .
Media Contact: Priyank Tiwari, RnR Market Research, + 1 888 391 5441, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
Jul. 23, 2016 11:00 AM EDT Reads: 429
Jul. 23, 2016 11:00 AM EDT Reads: 433
Jul. 23, 2016 11:00 AM EDT Reads: 1,115
Jul. 23, 2016 11:00 AM EDT Reads: 1,796
Jul. 23, 2016 10:45 AM EDT Reads: 1,947
Jul. 23, 2016 10:00 AM EDT Reads: 1,026
Jul. 23, 2016 10:00 AM EDT Reads: 1,882
Jul. 23, 2016 09:45 AM EDT Reads: 1,719
Jul. 23, 2016 09:45 AM EDT Reads: 948
Jul. 23, 2016 09:15 AM EDT Reads: 1,000
Jul. 23, 2016 09:00 AM EDT Reads: 808
Jul. 23, 2016 09:00 AM EDT Reads: 1,912
Jul. 23, 2016 08:30 AM EDT Reads: 649
Jul. 23, 2016 08:15 AM EDT Reads: 1,432
Much of IT terminology is often misused and misapplied. Modernization and transformation are two such terms. They are often used interchangeably even though they mean different things and have very different connotations. Indeed, it is somewhat safe to assume that in IT any transformative effort is likely to also have a modernizing effect, and thus, we can see these as levels of improvement efforts. However, many businesses are being led to believe if they don’t transform now they risk becoming ...
Jul. 23, 2016 08:00 AM EDT Reads: 1,044